ClinicalTrials.gg
RecruitingNCT07515599Updated Apr 7, 2026

Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension

An observational study in Stage 1 Hypertension, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. — 1 open to participants now, 3 under way, none of them phase 3. Hypertension · Daewoong Pharmaceutical Co. LTD..

Started
2025
with 1 other
Observational
5 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 15th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., or all of them as a file.
02

Study summary

This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.

Read the detailed description

This is a prospective, multicenter, observational study designed to evaluate the effectiveness of Olmetec® (olmesartan medoxomil) or Olmetec Plus® (olmesartan medoxomil/hydrochlorothiazide) on nocturnal blood pressure control in Korean patients with stage 1 hypertension.

In routine clinical practice, patients diagnosed with stage 1 hypertension and newly prescribed Olmetec® or Olmetec Plus® according to the approved label and the physician's clinical judgment will be enrolled and followed prospectively. No additional intervention beyond standard medical care will be applied.

Ambulatory blood pressure monitoring (ABPM) will be used to assess 24-hour blood pressure profiles, including nocturnal blood pressure, daytime blood pressure, and blood pressure variability. Measurements will be performed at baseline and after treatment to evaluate changes over time.

The primary objective of this study is to assess the change in mean systolic blood pressure from baseline to 12 weeks (up to 20 weeks). Secondary objectives include evaluation of diastolic blood pressure, nocturnal blood pressure, blood pressure variability, responder rate, and changes in dipping patterns. Safety will be assessed by monitoring adverse events during the study period.

This study aims to generate real-world evidence on the effectiveness and safety of Olmetec-based therapy in controlling nocturnal blood pressure and improving blood pressure variability in patients with stage 1 hypertension.

03

Conditions studied

  • Stage 1 Hypertension

Browse trials for

Keywords

  • hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with stage 1 hypertension in Korea who are newly prescribed Olmetec® or Olmetec Plus® according to routine clinical practice. Eligible patients are adults who meet the inclusion and exclusion criteria and are able to undergo ambulatory blood pressure monitoring (ABPM).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥19 years
  • Patients diagnosed with stage 1 hypertension according to clinical guidelines
  • Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice
  • Patients who are able to undergo ambulatory blood pressure monitoring (ABPM)
  • Patients who voluntarily agree to participate and provide written

Exclusion criteria

Exclusion Criteria:

  • Patients with secondary hypertension
  • Patients with severe hypertension requiring immediate pharmacological i-ntervention
  • Patients with known to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
  • Patients who are pregnant, planning to become pregnant, or breastfeeding
  • Patients with severe renal impairment or severe hepatic impairment
  • Patients who are unable to comply with study procedures, including ABPM
  • Patients who are deemed inappropriate for participation by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Olmetec-Based Treatment Cohort

    Patients with stage 1 hypertension who are prescribed Olmetec® or Olmetec Plus® as part of routine clinical practice will be included. Patients will be followed prospectively to assess changes in nocturnal blood pressure and blood pressure variability using ambulatory blood pressure monitoring (ABPM). No intervention beyond standard clinical care will be applied.

06

What researchers measure

Primary outcomes

  1. Change in mean 24-hour systolic blood pressure

    Change in mean 24-hour systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) from baseline to 12 weeks (up to 20 weeks).

    Time frame: Baseline to 12 weeks (up to 20 weeks)

Secondary outcomes

  1. Change in clinic systolic and diastolic blood pressure

    Change in clinic systolic and diastolic blood pressure from baseline.

    Time frame: Baseline to 12 weeks (up to 20 weeks)

  2. Responder rate

    Proportion of patients achieving systolic blood pressure \<140 mmHg or a reduction of ≥20 mmHg from baseline.

    Time frame: At 12 weeks (up to 20 weeks)

  3. Change in mean 24-hour diastolic blood pressure

    Time frame: Baseline to 12 weeks (up to 20 weeks)

  4. Change in nocturnal systolic and diastolic blood pressure

    Time frame: Baseline to 12 weeks (up to 20 weeks)

  5. Change in daytime systolic and diastolic blood pressure

    Time frame: Baseline to 12 weeks (up to 20 weeks)

  6. Change in blood pressure variability

    Change in variability indices of 24-hour, daytime, and nocturnal blood pressure.

    Time frame: Baseline to 12 weeks (up to 20 weeks)

  7. Change in dipping status (dipper/non-dipper proportion)

    Time frame: Baseline to 12 weeks (up to 20 weeks)

  8. Dipper conversion rate

    Time frame: At 12 weeks (up to 20 weeks)

  9. Change in morning blood pressure surge (MBPS)

    Time frame: Baseline to 12 weeks (up to 20 weeks)

  10. Change in pulse pressure

    Time frame: Baseline to 12 weeks (up to 20 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.

Of 81 industry-sponsored observational studies under Hypertension, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 10 months is below that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartActual
Sep 17, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07515599
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Sep 17, 2025
Primary completion
Jul 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Yun Jeong Kong
Contact
yjkong246@daewoong.co.kr
82-10-3206-5162

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion